News | Left Atrial Appendage (LAA) Occluders | January 18, 2018

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib

Biosense Webster, Inc. launches U.S. clinical study to evaluate the safety and efficacy of the WaveCrest Left Atrial Appendage Occlusion System

 

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib

January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled the first patient in the WaveCrest Investigational Device Exemption (IDE) Trial. The study will evaluate the safety and effectiveness of the WaveCrest Left Atrial Appendage Occlusion (LAAO) System in closure of the Left Atrial Appendage (LAA) and evaluate reduction of embolic stroke in atrial fibrillation (AFib) patients who cannot tolerate chronic Oral Anticoagulation Therapy (OAC).

The first patient was treated at New York University (NYU) Hospital by Larry Chinitz, M.D., a cardiac electrophysiologist and director of NYU Langone’s Heart Rhythm Center in New York City. The trial will enroll 1,250 patients at approximately 90 hospitals, and follow them for five years.

“The WaveCrest System is designed to enable physicians to close the heart’s LAA, where most stroke-causing blood clots occur,” said Chinitz. “For patients with AFib seeking an alternative to anticoagulants or blood thinners, this may be an important procedural option that could reduce the risk of stroke and save lives.”

According to the American Stroke Association, people with AFib have a five times higher risk of stroke than the general population. The Centers for Disease Control and Prevention (CDC) estimates 87 percent of all strokes are ischemic strokes, in which blood flow to the brain is blocked by the formation of a clot. Stroke is one of the most devastating and debilitating diseases, costing the United States an estimated $34 billion each year.

“Preventing and reducing the risk of stroke in AFib patients is a significant unmet need,” said Shlomi Nachman, company group chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “We are committed to investing in meaningful innovation and are excited by the prospect of bringing the WaveCrest System to the U.S. market so that more patients can benefit.”

The study is a prospective, multicenter, randomized, active controlled clinical trial of the WaveCrest Left Atrial Appendage Occlusion System compared to an existing FDA-approved LAA Closure Device for the reduction in risk of embolic stroke in subjects with non-valvular atrial fibrillation.

Although the device is under clinical study and not approved for use in the US, the WaveCrest Device is CE Mark approved and available in Europe.

For more information:  www.biosensewebster.com

 

Related Content

Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute
News | Left Atrial Appendage (LAA) Occluders | June 26, 2018
MedStar Heart & Vascular Institute physicians participating in a clinical trial have become the first in the Mid-...
A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman device in an echo image.

Feature | Left Atrial Appendage (LAA) Occluders | May 18, 2018
May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism f
AtriCure Launches AtriClip FLEX•V Device in the United States
Technology | Left Atrial Appendage (LAA) Occluders | February 22, 2018
February 22, 2018 — AtriCure Inc.
Videos | Left Atrial Appendage (LAA) Occluders | November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders | September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders | April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders | March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders | March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Overlay Init